MD Anderson Study Reveals New Insight Into DNA Repair

Jo-Carolyn Goode | 8/3/2015, 3:35 p.m.
The enzyme fumarase key to reversing genetic damage leading to cancer and therapy resistance
Zhimin Lu, M.D., Ph.D.

HOUSTON ― DNA double-strand breaks (DSBs) are the worst possible form of genetic malfunction that can cause cancer and resistance to therapy. New information published this week reveals more about why this occurs and how these breaks can be repaired.

Scientists at The University of Texas MD Anderson Cancer Center reported their findings about the role of the enzyme fumarase in DNA repair in the Aug. 3, 2015 issue of Nature Cell Biology.

“Our study showed that the enzymatic activity of the metabolic enzyme fumarase and its product, fumarate, are critical elements of the DNA damage response and that fumarase deficiency promotes tumor growth due to impairment of DNA repair,” said Zhimin Lu, M.D., Ph.D., professor of Neuro-Oncology.

Lu’s team demonstrated that fumarase accomplishes this through a process critical for gene regulation and expression known as histone methylation. Many cancers are thought to result from misregulated histone methylation.

Another crucial component of the DNA repair process is DNA-PK, a protein kinase that governs DNA damage response, helping to assure genetic stability. The researchers defined how DNA-PK and fumarase interact to increase histone methylation, allowing for DNA repair and restoration of healthy cells.

“We know that histone methylation regulates DNA repair, but the mechanisms underlying this repair has not been fully understood,” he said. “Our research revealed a ‘feedback’ mechanism that underlies DNA-PK regulation by chromatin-associated fumarase and the function of this fumarase in regulating histone methylation and DNA repair.”

This chain-of-event repair process occurs at the DSB regions and initiates a DNA damage “fix” by joining the tail ends of the double strand breaks.

Increasingly, inhibition of DNA-PKs and fumarase are being looked at for its potential to sensitize cancer cells to chemotherapy or radiotherapy. It is hoped a more thorough understanding about how they accomplish this can lead to new approaches to cancer treatment.

Dr. Lu’s group previously reported that another metabolic enzyme, pyruvate kinase M2 (PKM2) acts as a protein kinase in regulation of the Warburg effect, a process by which cancer cells produce energy, as well for regulation of gene expression and cell cycle progression.

“Our new findings on fumarase’s role in DNA repair further demonstrate that metabolic enzymes can possess non-metabolic functions in crucial cellular activities of cancer cells,” said Lu.

MD Anderson team members included Yuhui Jian, Ph.D., Yugang Wang, Ph.D., Xu Qian, Ph.D., Xinjian Li, Ph.D., Rui Liu, Ph.D., and Yan Xia, Ph.D., of the department of Neuro-Oncology; Jianfeng Shen, Ph.D. and Guang Peng, Ph.D., Clinical Cancer Prevention; and Shiaw-Yih Lin, Ph.D., Systems Biology.

Participating institutions included Shanghai General Hospital at Jiao Tong University, Shanghai, China, and Sichuan University, Chengdu, China.

The study was funded by the National Cancer Institute (2R01CAS109035, 1R0CA169603); the National Institute of Neurological Disorders and Stroke (1R01NS089754); the National Institutes of Health (CA0116672, 2P50CA127001); the James S. McDonnell Foundation 21st Century Science Initiative in Brain Cancer Research Award (220020318), and a Sister Institution Network Fund and the Odyssey Fellowship, MD Anderson.

About MD Anderson

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 45 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is ranked No. 1 for cancer care in U.S. News & World Report’s “Best Hospital’s” survey. It has ranked as one of the nation’s top two hospitals since the survey began in 1990, and has ranked first for 11 of the past 14 years. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

For more information, visit